A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Specific Aim: To establish the feasibility of studying the change in endothelial function
caused by induced moderate hyperbilirubinemia in type 1 diabetes. Atazanavir, a drug that
inhibits bilirubin conjugation, will be used to induce moderate hyperbilirubinemia.
Endothelial function will be measured before and after atazanavir therapy. In addition,
plasma markers of antioxidant capacity and oxidant stress will be measured as
proof-of-concept that induced moderate hyperbilirubinemia has favorable effects on oxidative
stress in type 1 diabetes.